Zealand Pharma A/S (Nasdaq: ZEAL) announced that results from its Phase 2 ZUPREME-1 trial evaluating petrelintide, an investigational weight management ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE